Hematologic Malignancies, Division of

People

  1. Shoushtari
    Shoushtari
  2. Young
    Young
  3. Geyer
    Geyer
  4. Epstein-Peterson
    Epstein-Peterson
  5. Shah
    Shah
  6. Peled
    Peled
  7. Vardhana
    Vardhana
  8. Tamari
    Tamari
  9. Dahi
    Dahi
  10. Intlekofer
    Intlekofer
  11. Maura
    Maura
  12. Jakubowski
    Jakubowski
  13. Tan
    Tan
  14. Caron
    Caron
  15. Goldberg
    Goldberg

Description

Publications

  1. Blood (3369)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)
  7. Blood Advances (226)
  8. Cancer Research (226)
  9. Leukemia and Lymphoma (214)
  10. Clinical Cancer Research (211)

Publishers

  1. American Society of Hematology (3636)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1265)
  4. Nature Publishing Group (988)
  5. Wiley Blackwell (430)
  6. American Association for Cancer Research (420)
  7. Ferrata Storti Foundation (292)
  8. Springer (289)
  9. Elsevier Science, Inc. (280)
  10. Taylor & Francis Group (274)

Sub-Groups

Types of Work

Recent Works

  1. Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: A plain language summary
    Review

    Marks, D. I.; Cassaday, R. D.; Ribera, J. M.; Schuh, A. C.; Park, J. H.; Chiaretti, S.; Stelljes, M.
    Expert Review of Hematology (2025)

    Fulltext@MSK | Save
  2. US geriatric assessment practices for older adults undergoing hematopoietic cell transplantation or chimeric antigen receptor T cell therapy: An American Society for Transplantation and Cellular Therapy Physician survey from the Aging Special Interest Group and Committee on Practice Guidelines
    Guidelines

    Munshi, P. N.; Olin, R. L.; Wall, S.; McCurdy, S. R.; Al-Juhaishi, T.; Baker, J.; Bhatt, V. R.; Chokr, N.; Dahi, P.; DeFilipp, Z.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  3. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: A randomized phase 3 trial
    Journal Article

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save